Cutaneous T-cell Lymphoma is rare form of Lymphoma that affect a small patient population. The rarity of the disease is a major challenge in front of the successful treatment of that condition. The heterogeneity of the disease especially of its mucousis fungoides form makes the diagnosis and therefore the proper treatment very difficult, because it is widely mistaken, by the medical specialists around the world with psoriasis. With the emerging of monoclonal antibodies like Alemtuzumab and the new pharmaceutical liposomal form of medicines like Doxorubicin, new treatment regiments for that condition are now available.
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R & Pimpinelli N. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome-Update. Eur J Cancer, 2017; 30(77): 57-74.
Netchiporouk E et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle, 2014; 13(21): S3331-3335.
Van Doorn R et al. Epigenomic analysis of Sezary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol, 2016; 136: 1876-84.
Flores-borja F et al. Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. Journal of immunology research, 2016; Article ID 7803091, 14 pages.
Willerslev-Olsen A et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016; 127(10): 1287-1296.
Munoz-Gonzalez H, Molina-Ruiz M & Requena L. Clinicopathologic Variants of Mycosis Fungoides. Actas Dermo-Sifiliograficas (English Edition), 2017; 108(3): 192-207.
Devata S & Wilcox RA. Cutaneous T-cell lymphoma: a review with a focus on targeted agents. Am J Clin Dermatol, 2016; 17(3): 225-237.
Lуpez-Lerma I & Estrach MT. Comparative analysis of the expression of cell adhesion molecules in cutaneous T-cell lymphomas (mycosis fungoides/Sezary syndrome) and inflammatory skin diseases. Actas Dermo-Sifiliograficas (English Edition), 2010; 101(10): 866-877.
Kavanaugh SA, White LA & Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Heal Pharm, 2010; 67(10): 793-797.
Wollina U, Langner D, Hansel G, & Haroske G. Pegylated liposomal- encapsulated doxorubicin in cutaneous composite lymphoma: A case report. Medicine, 2016; 95(43): e4796.
Email this article (Login required) 
